BALCAO · SERVICES-MEDICAL LABORATORIES
Renalytix PLC RNLXY
6 fiscal years on record · USD · FY2023 reported · SEC filings only
$-33.5M
Growth
USD 2.3M
Revenue, FY2023 · full 6-year series below
Revenue $M
Net income $M
FY2023 · Revenue 2.3 · Net income -33.5
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−1462 cents
lost on every revenue dollar
Operating margin
Net margin
FY2023 · Operating -1293.5% · Net -1461.6%
ROE
FY2022 · ROE -242.8%
The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.31 | −0.55 | −0.67 | −0.49 | −0.17 | −0.99 |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | · | −242.8 | −88.7 | −80.9 | −80.5 | −494.7 |
| Shares out B | 0.15 | 0.09 | 0.07 | 0.07 | 0.06 | 0.05 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 29 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 66 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Medical Laboratories
Listed onOTC market
Incorporated inoutside the United States — SEC code X0
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2018